Clinical study of irinotecan combined with suitable-symptom nutritional supporting treatment for advanced metastatic colorectal cancer
GENG Shu-mei
Abstract：Objective To evaluate the clinical efficacy and the toxicity of irinotecan combined with suitable-symptom nutritional supporting treatment for patients with advanced metastatic colorectal cancer who were intolerant of chemotherapy.Methods Twenty-four patients with tumor node metastases(TNM)stage Ⅳ advanced metastatic colorectal cancer were enrolled,and their Karnofsky performance status(KPS)score was 40-60.The observation group had 13 cases and the control group was 11 cases.The observation group was treated by irinotecan and suitable-symptom nutritional support; the control group was treated by suitable-symptom nutritional support.Results Tumor response rate of patients was 15.4％(2/13)in the observation group; the disease control rate was 53.8％(7/13).Survival rate of 1-year in the observation group was higher than that in the control group [53.8(7/13)vs 27.3(3/11),P ＜ 0.05]; KPS increasing rate was higher than that of the control group [53.8(7/13)vs 27.3(3/11),P ＜ 0.05].Adverse chemotherapy reaction was tolerable.Conclusions Disease control rate and 1-year survival rate in the observation group are significantly higher than those in the control group in advanced metastatic colorectal cancer.It can improve life quality.Patient tolerance and compliance are satisfactory.
Keywords：Advanced metastatic colorectal cancerIrinotecanSuitable-symptom nutritional support
Publication Date：2012-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)